Schlenk RF - Search Results

1

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Döhner H, et al. Among authors: schlenk rf. Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. Blood. 2014. PMID: 25006120 Free PMC article. Clinical Trial.

2

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P. Döhner H, et al. Blood. 1995 Mar 15;85(6):1580-9. Blood. 1995. PMID: 7888675 Free article.

3

Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.

Fischer K, Scholl C, Sàlat J, Fröhling S, Schlenk R, Bentz M, Stilgenbauer S, Lichter P, Döhner H. Fischer K, et al. Blood. 1996 Nov 15;88(10):3962-71. Blood. 1996. PMID: 8916963 Free article.

4

Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.

Schlenk RF, Döhner H, Pförsich M, Benner A, Fischer K, Hartmann F, Fischer JT, Weber W, Gunzer U, Pralle H, Haas R. Schlenk RF, et al. Br J Haematol. 1997 Nov;99(2):386-93. doi: 10.1046/j.1365-2141.1997.3933207.x. Br J Haematol. 1997. PMID: 9375760 Free article.

5

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.

Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R. Hohaus S, et al. Among authors: schlenk rf. Br J Cancer. 1999 Mar;79(9-10):1500-7. doi: 10.1038/sj.bjc.6690239. Br J Cancer. 1999. PMID: 10188897 Free PMC article.

6

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).

Voso MT, Martin S, Hohaus S, Abdallah A, Schlenk RF, Ho AD, Haas R. Voso MT, et al. Among authors: schlenk rf. Bone Marrow Transplant. 2000 May;25(9):957-64. doi: 10.1038/sj.bmt.1702336. Bone Marrow Transplant. 2000. PMID: 10800063

7

Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.

Döhner K, Schlenk RF, van der Reijden BA, Döhner H. Döhner K, et al. Among authors: schlenk rf. Leukemia. 2000 Jun;14(6):1154. doi: 10.1038/sj.leu.2401804. Leukemia. 2000. PMID: 10865983 No abstract available.

8

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.

Marcucci G, Caligiuri MA, Döhner H, Archer KJ, Schlenk RF, Döhner K, Maghraby EA, Bloomfield CD. Marcucci G, et al. Among authors: schlenk rf. Leukemia. 2001 Jul;15(7):1072-80. doi: 10.1038/sj.leu.2402159. Leukemia. 2001. PMID: 11455976

9

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Schlenk RF, et al. Leukemia. 2002 Apr;16(4):581-6. doi: 10.1038/sj.leu.2402423. Leukemia. 2002. PMID: 11960336 Clinical Trial.

10

Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia.

Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner H, Döhner K; Acute Myeloid Leukemia Study Group, Ulm. Fröhling S, et al. Among authors: schlenk rf. J Clin Oncol. 2002 May 15;20(10):2480-5. doi: 10.1200/JCO.2002.08.155. J Clin Oncol. 2002. PMID: 12011125

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page